Editas Medicine appoints Emma Reeve to Board as independent director

Editas Medicine, Inc.

Emma Reeve appointed independent Class III director effective September 3, 2021, until 2022 annual meeting.
She will serve on the Audit Committee and qualifies as an audit committee financial expert.
Ms. Reeve was SVP/CFO of Constellation Pharmaceuticals until its acquisition in July 2021.
Compensation includes $40,000 annual board retainer, $7,500 audit committee retainer, and option for 13,736 shares vesting over three years.
She also serves on the board of PTC Therapeutics since December 2018.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Emma Reeve

independent director

EDIT · Editas Medicine, Inc.

Effective: 2021-09-03
Filed: September 8, 2021, 7:59 PM ET

On September 3, 2021, the Board of Directors (the “Board”) of Editas Medicine, Inc. (the “Company”), upon recommendation of the Board’s Nominating and Corporate Governance Committee, increased the size of the Board by one member and appointed Emma Reeve as an independent director, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Emma Reeve was appointed as independent director at Editas Medicine, Inc..

Action: appointed
Role: independent director

Exact text from the filing

On September 3, 2021, the Board of Directors (the “Board”) of Editas Medicine, Inc. (the “Company”), upon recommendation of the Board’s Nominating and Corporate Governance Committee, increased the size of the Board by one member and appointed Emma Reeve as an independent director, effective immediately.

View on SEC.gov

Editas Medicine, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-21-012312

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.